Archive · 27 Jul 2026
Sakar Healthcare Jumps 4% on Strong Q1FY27 Results
Sakar Healthcare, a pharmaceutical company based in Ahmedabad, Gujarat, reported strong financial results for the first quarter of the fiscal year 2027.
The company's revenue increased by 38% year-over-year, and net profit surged by 120%.
This growth was driven by new market authorisations for oncology products, strong demand, and effective business strategies.
The stock price of Sakar Healthcare jumped by over 4% on the NSE during the intraday session on Monday.
Despite a 9% drop in the past week, the stock has delivered impressive returns of 101% year-to-date and 354% over the past five years.
Investors are optimistic about the company's future growth prospects, while market volatility remains a concern.
Sakar Healthcare reported a 38% YoY increase in revenue to ₹72.97 crore in Q1FY27.
Net profit surged 120% YoY to ₹10.28 crore, with PAT margin expanding to 14%.
EBITDA rose 67% YoY to ₹21.25 crore, with EBITDA margin improving to 29%.
The stock price jumped over 4% on the NSE during the intraday session on Monday.
The company has delivered multibagger returns of 101% year-to-date and 354% over five years.
- Who
- Sakar Healthcare Limited
- What
- Reported strong Q1FY27 results with a 120% YoY rise in net profit
- When
- 25 July 2026
- Where
- Ahmedabad, Gujarat, India
- Why
- Driven by new market authorisations for oncology products, robust demand, and steady execution of key business initiatives
Investor Optimism
Market Volatility
Stock Performance
Investor Optimism
Investors are optimistic about Sakar Healthcare's strong financial performance and future growth prospects.
Market Volatility
The stock has experienced a 9% drop in the past week, indicating market volatility.
- Company
- Sakar Healthcare Limited
- Headquarters
- Ahmedabad, Gujarat
- Founded
- 2004
- Q1FY27 Revenue
- ₹72.97 crore
- Q1FY27 Net Profit
- ₹10.28 crore
- Year-to-Date Returns
- 101%
- Three-Year Returns
- 213%
- Five-Year Returns
- 354%